[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucocorticoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucocorticoid":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100631309","glucocorticoid-ozone-and-5-dextrose-local-injection-for-pain-relief-in-carpal-tunnel-syndrome-100631309",false,"NCT07498998","Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome","A Comparative Study Between Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Adults aged 18-65 years with a clinical diagnosis of mild to moderate Carpal Tunnel Syndrome .\n* Clinical diagnosis of mild to moderate Carpal Tunnel Syndrome , as classified by Bland neurophysiological classification scale: Mild Carpal Tunnel Syndrome : Slow Distal Sensory Latency(≥3.6 ms), Normal Distal Motor Latency(\\\u003C 4.5 ms)\n* Moderate Carpal Tunnel Syndrome : Slow Distal Sensory Latency (≥ 3.6 ms), Slow Distal Motor Latency (4.5 - 6.4 ms)\n* Failure to respond to conservative treatments (e.g., splinting, activity modification, or oral medications) for at least 6 weeks.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Severe Carpal Tunnel Syndrome requiring surgical intervention, as defined by the Bland neurophysiological classification scale: Severe Carpal Tunnel Syndrome: Absent Distal Sensory Latency and Slow Distal Motor Latency (4.5 - 6.4 ms)\n* Previous corticosteroid injection for Carpal Tunnel Syndrome within the last 6 months.\n* History of wrist trauma, surgery or anatomical abnormalities.\n* Systemic conditions such as diabetes mellitus, thyroid dysfunction or rheumatoid arthritis.\n* Pregnancy or lactation.\n* Contraindications to any of the study interventions (e.g., allergy to glucocorticoids or ozone).\n* Infection at wrist.","ALL","18 Years","65 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to compare the efficacy and outcomes of perineural injection with 5% dextrose, local ozone and glucocorticoid injection in the management of carpal tunnel syndrome.",[27,28,29,30],"Carpal Tunnel Syndrome (CTS)","Glucocorticoid","Pain","Dextrose",[32,33,34,35],"glucocorticoid","Ozone","5% dextrose","carpal tunnel syndrome","NOT_YET_RECRUITING","2026-03-24",{"date":39,"type":40},"2026-03-27","ACTUAL",{"date":42,"type":21},"2026-07-30",{"date":44,"type":21},"2026-08-30",{"name":46,"class":47},"Tanta University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":48},"100609345","phase-2-high-dose-dexamethasone-to-reduce-postoperative-pain-after-video-assisted-thoracoscopic-surgery-lobectomy-segmentectomy-100609345","NCT07213375","High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy \u002FSegmentectomy","High Dose Dexamethasone In High-Pain Responders Undergoing Enhanced Recovery Video-Assisted Thoracoscopic Surgery Lobectomy and Segmentectomy - A Randomized Double-Blinded Controlled Trial","DEXTER","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Able to understand written and spoken Danish language\n* PCS ≥20\n* Signed written informed consent form.\n* Patient planned to elective VATS lobectomy\u002Fsegmentectomy\n\nExclusion Criteria:\n\n* Patients undergoing systemic glucocorticoid or other immunosuppressive therapies, ex-cluding inhaled steroids.\n\n  * Individuals with diabetes requiring insulin treatment.\n  * Pregnant or breastfeeding patients.\n  * Patients with known allergies to the study drug.\n  * Individuals with mental disabilities that may impair their capacity to provide informed consent or compromise the validity of data collection.\n  * Patients with diagnosed schizophrenia, active psychosis, bipolar disorder, or a history of ongoing treatment with antipsychotic and\u002For antidepressant medications.\n  * Individuals with altered pain perception due to other conditions or injuries, such as spi-nal cord or brain injuries, severe polyneuropathies, or neurological disorders.\n  * Regular users of opioid medications.\n  * Patients requiring reoperation within the first two postoperative days.\n  * Individuals undergoing conversion to a surgical procedure other than VATS lobecto-my\u002Fsegmentectomy.",{"count":58,"type":21},80,[60,61],"PHASE2","PHASE3","The aim is to conduct a randomized controlled trial (RCT) with a high dose arm (1mg\u002Fkg) vs a low dose (8mg in total) of steroid (Dexamethasone) given intravenous (IV) after the induction of anesthesia to \"High-pain-responders\" in patients undergoing VATS lobectomy\u002Fsegmentectomy.\n\nThe hypothesis is that a high dose of Dexamethasone can lower pain when coughing in the morning after VATS lobectomy\u002Fsegmentectomy, in patients scoring as \"High-pain-responders\" on the Pain-Catastrophizing-Scale",[64,65,66,28],"Analgetic","Lung Cancer (NSCLC)","Video Assisted Thoracic Surgery (VATS)",[68,69,70,71,72],"Pain catastrophizing","ERAS","VATS","Lung cancer","Minimizing pain","RECRUITING","2026-01-05",{"date":76,"type":40},"2026-01-07",{"date":78,"type":40},"2025-09-01",{"date":80,"type":21},"2026-11",{"name":82,"class":47},"Rigshospitalet, Denmark",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":48},"100566393","efficacy-and-safety-of-telitacicept-in-igan-100566393","NCT06654596","Efficacy and Safety of Telitacicept in IgAN","A Multicenter, Randomized, Controlled Clinical Study on the Efficacy and Safety of Telitacicept in Patients with IgA Nephropathy","Inclusion Criteria:\n\n1. 18-70 years old, male or female\n2. Primary IgA nephropathy confirmed by renal biopsy.\n3. Urine protein ≥ 0.75g\u002F24h or 24-hour urine protein creatinine ratio (PCR) ≥ 0.6 g\u002Fg.\n4. eGFR ≥ 25 ml\u002Fmin\u002F1.73 m2 calculated using the CKD-EPI formula.\n5. Received treatment with ACEI\u002FARB for 12 weeks before randomization, and the drug dose (within the maximum tolerated range) was stable within 4 weeks before randomization.\n6. Use of SGLT2, MRA, hydroxychloroquine, and etc. remained unchanged.\n7. Voluntarily participated in this study and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with abnormal laboratory indicators (see study protocol for details).\n2. Secondary IgA nephropathy such as Henoch-Schonlein purpura, SLE, cirrhosis, etc.\n3. Use of systemic glucocorticoids\u002Fimmunosuppressants within 3 months (such as cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, tripterygium wilfordii, etc.).\n4. Use of biological agents within 6 months (rituximab, etc.).\n5. Active infection, such as active tuberculosis, active hepatitis, hepatitis C, herpes zoster, HIV, etc. According to the results of the five hepatitis B test: patients with positive HBsAg should be excluded; patients with negative HBsAg but positive HBcAb, regardless of whether HBsAb is positive or negative, need to test HBV-DNA to determine their situation: if HBV-DNA is positive, the patient needs to be excluded; if HBV-DNA is negative, the patient can participate in the trial.\n6. COVID-19 infection within 2 weeks before randomization.\n7. Live vaccine within 4 weeks before randomization.\n8. History of malignant tumor within five years.\n9. Uncontrolled hypertension (systolic blood pressure\\>140mmHg or diastolic blood pressure\\>90mmHg).\n10. Poorly controlled diabetes (glycosylated hemoglobin\\>8%).\n11. Pregnant women and breastfeeding women.\n12. Participating in other clinical trials at the same time.\n13. Surgery, chemotherapy, radiotherapy and other treatments are planned during the study.\n14. Other reasons judged by researchers as unsuitable for inclusion in the study.","70 Years",{"count":92,"type":21},118,[24],"A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.",[96,97,98,28],"IgA Nephropathy (IgAN)","Kidney Diseases","Telitacicept","2024-12-30",{"date":101,"type":40},"2025-01-01",{"date":103,"type":40},"2024-12-06",{"date":105,"type":21},"2026-12",{"name":107,"class":47},"Ruijin Hospital"]